Janet Woodcock’s Mission: Predict Adverse Events, ID Them After They Happen
Executive Summary
FDA's drug safety reforms in response to the Institute of Medicine's report include emphasizing the newly created position of chief medical officer
You may also be interested in...
FDA Reform Bill Leaves Senate With Reduced Safety Powers But Stiffer Fines
Legislation to reauthorize FDA's user fee program and expand the agency's oversight powers on drug safety has cleared the Senate with much stronger fines than originally envisioned by the sponsors, thanks to an amendment by Sen. Charles Grassley, R-Iowa
FDA Reform Bill Leaves Senate With Reduced Safety Powers But Stiffer Fines
Legislation to reauthorize FDA's user fee program and expand the agency's oversight powers on drug safety has cleared the Senate with much stronger fines than originally envisioned by the sponsors, thanks to an amendment by Sen. Charles Grassley, R-Iowa
FDA To Re-Evaluate Safety Of NMEs In Pilot Postmarket Monitoring Program
FDA will prepare safety profiles for several new molecular entities, using data from the first year of post-market experience, under a pilot program that is part of the agency's response to the Institute of Medicine's recommendations for improving drug safety in the United States